Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224) by Doñate, F et al.
Identification of biomarkers for the antiangiogenic and antitumour
activity of the superoxide dismutase 1 (SOD1) inhibitor
tetrathiomolybdate (ATN-224)
F Don ˜ate*,1, JC Juarez
1, ME Burnett
1, MM Manuia
1, X Guan
1, DE Shaw
2, ELP Smith
3, C Timucin
3,
MJ Braunstein
3, OA Batuman
3 and AP Mazar
1
1Attenuon, LLC, San Diego, CA 92121, USA;
2DE Shaw Research, LLC, New York, NY 10036, USA;
3Division of Hematology and Oncology, State
University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA
Tetrathiomolybdate (choline salt; ATN-224), a specific, high-affinity copper binder, is currently being evaluated in several phase II
cancer trials. ATN-224 inhibits CuZn superoxide dismutase 1 (SOD1) leading to antiangiogenic and antitumour effects. The
pharmacodynamics of tetrathiomolybdate has been followed by tracking ceruloplasmin (Cp), a biomarker for systemic copper.
However, at least in mice, the inhibition of angiogenesis occurs before a measurable decrease in systemic copper is observed. Thus,
the identification and characterisation of other biomarkers to follow the activity of ATN-224 in the clinic is of great interest. Here, we
present the preclinical evaluation of two potential biomarkers for the activity of ATN-224: (i) SOD activity measurements in blood
cells in mice and (ii) levels of endothelial progenitor cells (EPCs) in bonnet macaques treated with ATN-224. The superoxide
dismutase activity in blood cells in mice is rapidly inhibited by ATN-224 treatment at doses at which angiogenesis is maximally
inhibited. Furthermore, ATN-224 dosing in bonnet macaques causes a profound and reversible decrease in EPCs without significant
toxicity. Thus, both SOD activity measurements and levels of EPCs may be useful biomarkers of the antiangiogenic activity of
ATN-224 to be used in its clinical development.
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Angiogenesis, the process of formation of new blood vessels from
pre-existing ones, is critical for tumour growth and a promising
therapeutic target for the treatment of cancer (Carmeliet, 2005;
Don ˜ate, 2005; Ferrara and Kerbel, 2005). Tetrathiomolybdate (TM)
is an orally available copper-binding compound that has been
shown to have efficacy as an antiangiogenic and antitumour agent
in several mouse models of cancer (Pan et al, 2002, 2003a,b;
Lowndes and Harris, 2004; Goodman et al, 2005; Hassouneh et al,
2007), and has also been tested as an anticancer therapy in several
clinical trials (Brewer et al, 2000; Redman et al, 2003). The ability
of TM to inhibit angiogenesis has been attributed to the depletion
of systemic copper, which has been described to affect multiple key
regulators of angiogenesis (Brewer et al, 2000; Pan et al, 2002,
2003a,b; Redman et al, 2003; Goodman et al, 2005; Hassouneh
et al, 2007). ATN-224 is a second-generation choline salt of TM
with improved stability, which has been tested in two phase I
clinical trials (solid tumours and haematological malignancies)
(Berenson et al, 2006; Lowndes et al, 2006) and is currently being
investigated in three phase II trials (melanoma, prostate and
multiple myeloma). We have recently identified the copper-
dependent enzyme superoxide dismutase 1 (SOD1) as the main
target for the antiproliferative activity of ATN-224 in endothelial
and tumour cells (Juarez et al, 2006). Superoxide dismutase 1 is an
abundant cytosolic enzyme that dismutates superoxide into
hydrogen peroxide and molecular oxygen. The SOD1 activity in
erythrocytes has been proposed as a biomarker for copper status
in humans (Uauy et al, 1985; Milne, 1998).
Collectively, the data on TM and ATN-224 strongly support the
notion that the biological activity of TM in vivo has a robust
antiangiogenic component (Brewer et al, 2000; Pan et al, 2002,
2003a,b; Redman et al, 2003; Lowndes and Harris, 2004; Goodman
et al, 2005; Juarez et al, 2006; Hassouneh et al, 2007). Although
ATN-224 has also been shown to have antiproliferative and/or
proapoptotic effects on tumour cells in vitro (Juarez et al, 2006), it
is yet unclear whether sufficiently high concentrations of ATN-224
can be achieved and maintained in the tumour environment
in vivo to elicit those responses.
Ceruloplasmin (Cp) is a copper-containing oxidase, which is
synthesised in the liver and circulated in blood. Cp contains
approximately 95% of all copper in the blood; however, despite
its high copper content, the role of Cp in copper transport is
controversial. For example, targeted disruption of the Cp gene in
mice does not alter copper absorption, transport or distribution
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s(Meyer et al, 2001). Furthermore, patients with aceruloplasminae-
mia who lack a functional Cp have normal copper metabolism
(Vassiliev et al, 2005). Although copper deficiency does not seem
to directly affect the synthesis or secretion of Cp from the liver, the
resulting apoprotein has a shorter half-life than that of the holo-
Cp, and serum Cp measurements have been used to follow copper
depletion: and pharmacokinetics (PK) and pharmacodynamics
(PD) in clinical trials evaluating TM in cancer patients (Brewer
et al, 2000; Redman et al, 2003; Lowndes and Harris, 2004;
Goodman et al, 2005). However, the decrease in Cp levels may lag
behind the onset of copper depletion, since apo-Cp is formed and
degraded at a certain rate. Furthermore, we have observed that the
inhibition of angiogenesis in mice by ATN-224 occurs before a
measurable decrease in systemic copper is observed (Juarez et al,
2006). Thus, the identification of other biomarkers that may aid in
the clinical development of ATN-224 is of interest.
MATERIALS AND METHODS
Reagents
ATN-224 (choline tetrathiomolybdate) was manufactured under
cGMP using a proprietary manufacturing process with 499%
purity. The ATN-224 stocks (50mgml
 1) were prepared in water,
and aliquoted and frozen until use. ATN-224 was diluted to the
desired concentration using phosphate-buffered saline (PBS) or
media just prior to use. Blood was drawn from human volunteers
into Vacutainer tubes (BD Biosciences, San Jose, CA, USA)
containing citrate. Plasma and blood pellets were obtained by
centrifugation. Blood cells were washed twice with PBS and
analysed for SOD activity. Bovine SOD1 was acquired from Sigma
(St Louis, MO, USA).
Matrigel plug
The Matrigel plug model was carried out as described before
(Juarez et al, 2002). Briefly, cold Matrigel (BD) (500ml) was mixed
with 800ngml
 1 of FGF-2 or 300ngml
 1 of VEGF and heparin
(50mgml
 1). Negative control plugs did not contain the proangio-
genic factors. The Matrigel mixture was injected subcutaneously
(s.c.) into 4- to 8-week-old female BALB/c nude mice. Mice were
treated by oral gavage either with distilled water or ATN-224.
Animals were killed and the plugs recovered 5 days post plug
injection. The haemoglobin levels in the plugs were determined
using Drabkin’s solution according to the manufacturers’ instructions
(Sigma).
SOD assays
Blood pellets were lysed by adding an equal volume of RIPA buffer.
A 1:20 dilution of the lysate was carried out in Tris-buffered saline
(1:10 for plasma samples) and protein concentration determined
by the Bradford assay (Bio-Rad, Hercules, CA, USA). Thirty
micrograms (60mg for plasma samples) were assayed as follows:
SOD1 activity was determined by measuring the inhibition of
reduction of the water-soluble tetrazolium salt, WST-1 (2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-phenyl)-2H-tetrazolium,
monosodium salt), which produces a water-soluble formazan dye
upon reduction with a superoxide anion (Dojindo Molecular
Technologies, Gaithersburg, MD, USA). Superoxide anion is
generated by xanthine oxidase. Bovine SOD (Sigma), which has
been shown to be equivalent to human SOD (Juarez et al, 2006),
was used to generate a standard curve.
Molybdenum levels
The concentration of ATN-224 in blood was determined by
measuring molybdenum (Mo) using ICP-MS. Cell extracts or
whole tissues were sent to ERI (Vancouver, BC, Canada) for
analysis. Cells and tissues were digested using 6 N HNO3 to
completely release all metals prior to analysis.
Animal studies with mice
A431 cells from ATCC were grown in Dulbecco’s modified eagle
media, 10% fetal bovine serum at 371C in a humidified 5% CO2
incubator. Two million cells were injected s.c. into female BALBc
nude mice. When tumours reached 200–300mm
3, animals were
randomised and treatment started. For some experiments, animals
were treated daily with water, 50 or 150mgkg
 1 of ATN-224 by
oral gavage. Animals were killed 10 days later, 3h after the last
dose of ATN-224. In other experiments, animals received water, or
100mgkg
 1 ATN-224 by oral gavage and were killed at different
times. In both cases, tumours were isolated and blood was drawn.
All animal procedures were performed according to approved
protocols and in accordance with the recommendations for the
proper care and use of laboratory animals. These studies were
carried under the Institutional Animal Care and Use Committee
(IACUC) from Perry Scientific (San Diego, CA, USA).
Animal studies with bonnet macaques
Subjects Subjects were three female and three male bonnet
macaques (Macaca radiata), with a mean age of 12.9 years
(s.e.¼0.84), corresponding to early to mid-adulthood in this
species. Subjects were singly housed in the same temperature- and
humidity-controlled room. Lighting was on a 12:12h light/dark
cycle. Water and standard laboratory chow were available ad
libitum.
ATN-224 administration Cages had a movable back by which
subjects could be brought to the front of the cage for injection of
ATN-224 (0.5mgkg
 1, s.c.). Injections began with a different
monkey each day. Monkeys initially received ATN-224 for 22
consecutive days, followed by a drug holiday for 26 days. Drug
injections then resumed for 33 out of the next 35 days and
ATN-224 was given 15min before lights went off at night.
Blood sampling Blood samples were always taken between 0900
and 1100 hours, and the order in which the subjects were sampled
was systematically varied. The monkey was brought to the front of
the cage by means of the movable cage back, and was given an
injection of ketamine (10–15mgkg
 1, i.m.), immediately placed in
a carrying cage, removed from the colony room and allowed to sit
undisturbed for 10–15min outside the veterinary treatment room
a few feet away. The anaesthetised monkey was then taken from
the carrying cage, the inner femoral area was shaved and
disinfected, and approximately 10ml of blood was withdrawn
from the femoral triangle. The blood was deposited in tubes with
and without EDTA, and placed on ice. If insufficient blood was
drawn from the femoral triangle, additional blood was collected
from the cephalic vein. All animal procedures were performed
according to approved protocols and in accordance with the
recommendations for the proper care and use of laboratory
animals. These studies were approved by the IACUC from SUNY
Downstate Medical Center.
EPC quantitation Mononuclear cells were harvested from
peripheral blood samples using Ficoll–Hypaque (Sigma) density-
gradient centrifugation, followed by exposure of separated cells to
a red blood cell lysis buffer (Roche Applied Science, Indianapolis,
IN, USA). Direct immunofluorescence using combinations of
monoclonal antibodies including anti-CD31-FITC (BD Biosciences);
anti-CD133-PE (Miltenyi Biotec, Auburn, CA, USA) and anti-
CD45-PE/Cy5 (eBioscience, San Diego, CA, USA) was performed as
previously described (Zhang et al, 2005). Cells were analysed by
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sthree-colour flow cytometry using a FACSort flow cytometer (BD
Biosciences) using the CellQuest software program (BD Immuno-
cytometry Systems, San Diego, CA, USA) with appropriate
compensation.
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Figure 1 ATN-224 inhibits SOD activity in blood cells. Anticoagulated
blood from three volunteers was incubated with ATN-224 (0, 1 and
10mM) for 5.5h at 371C, and plasma and blood pellets were prepared by
centrifugation. (A) ATN-224 inhibits the SOD activity in blood pellets. The
SOD activity was measured in blood pellets as described in Materials and
Methods. (B) Levels of molybdenum are in agreement with SOD activity
measurements. Molybdenum content was measured using ICP-MS for the
same samples analysed for SOD activity.
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Figure 2 Inhibition of the SOD activity in human and mouse blood cells
by ATN-224. (A) ATN-224 inhibits the SOD activity in human blood cells.
Human anticoagulated blood from volunteers was incubated with different
concentrations of ATN-224 overnight, and intracellular SOD activity was
measured as described in Materials and Methods. Three different
experiments are shown. ATN-224 inhibited SOD activity with an
IC50¼2.91±0.48mM.( B) ATN-224 inhibits the SOD activity of mouse
blood cells. Mouse anticoagulated blood was incubated with different
concentrations of ATN-224 overnight, and intracellular SOD activity was
measured as described in Materials and Methods. Three different
experiments are shown. ATN-224 inhibited SOD activity with an
IC50¼3.51±1.7mM.( C) The IC50 of ATN-224 for purified SOD1 activity
increases in the presence of human plasma. Purified bovine SOD1
(5Uml
 1) was incubated with human plasma overnight, and SOD activity
was measured as described in Materials and Methods. The SOD
activity measured in human plasma is negligible. ATN-224 inhibited SOD
activity with an IC50¼2.03mM.
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sStatistical analysis
GraphPad software was used for all statistical analysis. Data are
presented as mean±s.d. Data were analysed using unpaired, two-
tailed t-tests when comparing two variables. Analysis of variance
with Tukey’s posttest was used to compare data in experiments
where more than two variables were compared simultaneously.
RESULTS
As ATN-224 treatment inhibits SOD activity in endothelial and
tumour cells (Juarez et al, 2006), the effect of ATN-224 on SOD
activity in blood cells was tested. Superoxide dismutase 3 is also a
copper-dependent enzyme, which is bound to the extracellular
matrix in mammalian tissues (Nozik-Grayck et al, 2005). It is
mainly produced by vascular smooth muscle cells and retained in
the vascular wall, and therefore mainly absent in erythrocytes and
other blood cells (Nozik-Grayck et al, 2005). Superoxide dismutase
3 is mainly responsible for the SOD activity found in plasma and
serum (Nozik-Grayck et al, 2005; Tasaki et al, 2006), and decreased
copper levels inhibit its activity in rats (Johnson et al, 2005).
Superoxide dismutase 3 activity in human plasma is low, but
increases upon treatment with heparin (Tasaki et al, 2006). Blood
from laboratory personnel who had volunteered for venipuncture
was drawn and samples were incubated with ATN-224 for 5.5h at
371C. Plasma and blood pellets were prepared after incubation
with ATN-224 and SOD activity and molybdenum (Mo) levels were
determined. The levels of SOD activity in plasma from human
volunteers were below the detection limits of our assay (data not
shown) in agreement with the low levels of SOD3 that have been
reported in plasma of humans (Tasaki et al, 2006). Figure 1A
shows that ATN-224 inhibited SOD activity in blood cell pellets in
a dose-dependent manner in agreement with the levels of Mo
(representing ATN-224) associated with the cells (Figure 1B).
ATN-224 inhibits SOD1 by removing copper from the active site
(Juarez et al, 2006). As expected, it does not inhibit Escherichia coli
SOD (data not shown), a manganese-containing enzyme. Further-
more, the majority of the SOD activity in blood cell lysates comes
from SOD1 and not SOD2: as a SOD1-specific inhibitor (KCN)
decreased the measured total SOD activity to background levels
(data not shown). Thus, despite the fact that we used whole cell
extracts, we only observed SOD1 in this assay. Next, the IC50 for
the inhibition of SOD activity by ATN-224 in human and mouse
blood cells was measured (Figures 2A and B) according to the
protocol used in Figure 1, except that blood samples were
incubated with ATN-224 overnight. The determined IC50 was
approximately 3mM for human and mouse blood cell SOD1. The
IC50 for inhibition of purified SOD1 is 300nM (Juarez et al, 2006),
which is B10-fold lower than the IC50 for SOD1 in blood cells. In
the presence of albumin and presumably copper, ATN-224 forms a
complex that is inactive in an endothelial proliferation assay
(Juarez et al, 2006), and we suspected that the formation of that
complex in blood could explain the higher IC50 against blood cells.
This possible matrix effect in blood was tested by assaying purified
bovine SOD1 in fresh human plasma instead of buffer and
determining an IC50 for ATN-224 inhibition. The IC50 under these
conditions was B2mM (Figure 2C), approximately seven-fold
higher than that needed to inhibit purified SOD1, suggesting that a
proportion of the ATN-224 in plasma is inactivated by forming a
tripartite complex with albumin and copper. The data presented
thus far supports the notion that ATN-224 inhibits SOD activity in
blood cells and that the dose at which that occurs may reflect the
level of active compound.
Both in tumour models (Pan et al, 2002, 2003a,b; Hassouneh
et al, 2007) and in in vivo angiogenesis models, such as the
Matrigel plug model (Juarez et al, 2006), ATN-224 has a strong
antiangiogenic activity, and we wished to establish a relationship
between the dose needed to inhibit angiogenesis and that needed
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Figure 3 Plasma extracellular SOD, blood cell SOD and angiogenesis
(Matrigel plug model) are inhibited in mice at different doses of ATN-224.
(A and B) The ATN-224 dosing inhibits the SOD activity in plasma (A)
and blood cells (B). Blood was collected after 5 days dosing with ATN-224,
centrifuged and plasma and cell pellets were isolated. Superoxide dismutase
activity was measured as described in Materials and Methods. In (A), two
titrations (black and white bars) were carried out, and the 0 and 50mgkg
 1
data points are included in the second titration for comparison purposes
with the first titration. (C) ATN-224 inhibits angiogenesis in the Matrigel
plug model in a dose-dependent manner. Mice were treated daily for 5
days by oral gavage with the indicated amounts of ATN-224 or vehicle
control. Angiogenesis was measured by measuring haemoglobin levels as
indicated in the Materials and Methods section; **Po0.01, ***Po0.001
(t-test).
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sto inhibit SOD activity in blood cells. Mice were dosed daily by
gavage with different doses of ATN-224 for 5 days and SOD activity
was determined in plasma and blood pellets at the end of the
experiment (Figures 3A and B). In contrast to our results with
human plasma (see above), mouse plasma SOD activity was easily
detectable and ATN-224 treatment inhibited SOD activity indicat-
ing that SOD3, primarily responsible for SOD activity in plasma,
can also be inhibited by ATN-224. In a second experiment, a dose
titration for ATN-224 in the mouse Matrigel plug model was
carried out (Figure 3C). The IC50 was determined to be
approximately 1.50–3mgkg
 1 and a dose of 50mgkg
 1 produced
an inhibition of 82% in the Matrigel plug assay. The 50mgkg
 1
dose is similar to a dose used before to optimally inhibit tumour
growth and angiogenesis in tumour-bearing mice (35–50mgkg
 1
TM, which is equivalent to 59–85mgkg
 1 ATN-224 on a molar
basis) (Pan et al, 2002, 2003a,b; Hassouneh et al, 2007). Doses of
50 and 250mgkg
 1 were needed to completely inhibit SOD activity
in plasma and blood pellets, respectively, suggesting that inhibi-
tion of SOD activity occurs at doses at which angiogenesis is
maximally inhibited.
The ATN-224 treatment also inhibited SOD activity in A431
tumours grown s.c. in mice (Figure 4). Unlike human tumours,
experimental tumours grown s.c. in mice lack significant stroma,
and therefore, the majority of the tumour mass is made up of
tumour cells per se. Tumour-bearing mice were treated with buffer
control, 50 or 150mgkg
 1 of ATN-224 daily by oral gavage for 10
days. The 50mgkg
 1 dose is similar to a dose used before to
optimally inhibit tumour growth and angiogenesis in tumour-
bearing mice (35–50mgkg
 1 TM, which is equivalent to 59–
85mgkg
 1 ATN-224 on a molar basis) (Pan et al, 2002, 2003a,b;
Hassouneh et al, 2007). At the end of the treatment, the mice were
killed, and the tumours were removed and lysed. The SOD activity
in controls and ATN-224-treated mice was measured. The SOD
assays were carried out using either 30 or 60mg of total extracted
protein and the SOD activity (Uml
 1) calculated from a standard
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Figure 5 Inhibition of tumour cell SOD after a single dose of ATN-224 in A431 tumour-bearing mice. Mice were given a 100mgkg
 1 dose by oral gavage
of ATN-224. At the indicated times, mice were killed and blood and tumours collected. (A) A single dose of ATN-224 inhibits the SOD activity in tumours
in a time-dependent manner. Mice were killed at the indicated times and tumours resected, minced and lysed. Superoxide dismutase 1 activity was measured
as described in Materials and Methods. (B) A single dose of ATN-224 inhibits the SOD activity in plasma in a time-dependent manner. (C) A single dose of
ATN-224 inhibits the SOD activity in blood cells in a time-dependent manner; *Po0.05 (t-test). (D) Levels of molybdenum agree with SOD activity
measurements. Molybdenum content in plasma and blood cells was measured using ICP-MS.
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Figure 4 Inhibition of tumour cell SOD by ATN-224 in an A431
xenograft model. Tumour-bearing mice were treated daily for 10 days by
oral gavage with the indicated amounts of ATN-224 or vehicle control.
Tumours were minced and lysed. Superoxide dismutase 1 activity was
measured as described in Materials and Methods; ***Po0.001 (t-test).
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scurve generated using purified SOD as a standard. The 50mgkg
 1
dose of ATN-224 resulted in an approximately 26% reduction of
the SOD activity, whereas the 150mgkg
 1 dose inhibited SOD by
65% (Po0.001) when compared with control mice. Similarly,
when A549 tumour-bearing mice were treated for 10 days with
100mgkg
 1 daily of ATN-224, the SOD activity in the tumour was
inhibited by B80% (data not shown). Next, we wished to
investigate the kinetics of the SOD inactivation in tumours after
a single dose of ATN-224 (100mgkg
 1) in A431 tumour-bearing
mice. The results showed a significant inhibition of the SOD
activity in the tumour, which was maximal at 12h and returned to
normal levels 24h after treatment (Figure 5A). Similar results were
observed in a second experiment (data not shown) in which the
SOD activity and molybdenum levels in plasma and blood pellets
were also measured (Figures 5B–D). As expected, the SOD activity
in plasma is almost completely inhibited, but it appears to take
longer to recover than in the tumour (Figure 5B). The SOD activity
in the blood pellet is also inhibited (Figure 5C), but the level of
inhibition is significantly variable among mice within the same
time point. This variability is not due to differences in the level of
drug as the concentration of Mo does not change significantly
within mice in the same group (Figure 5D). This variability is not
observed in mice that have been treated for 5 or 10 days with ATN-
224. Altogether, these data indicate that SOD1 inhibition can be
detected even after a single dose of ATN-224 in the tumour, plasma
and blood cells, much earlier than the detection of decreases in Cp
are observed in mice or humans (Lowndes and Harris, 2004;
Goodman et al, 2005). This suggests that the SOD inhibition in
blood and blood cells is a faster and more sensitive read-out of the
biological activity of ATN-224. This is also consistent with our
earlier observation that inhibition of angiogenesis takes place
before systemic copper depletion is achieved (Juarez et al, 2006).
The levels of circulating endothelial cells (CECs) and endothelial
progenitor cells (EPCs) increase in several pathological conditions,
including cancer (Bertolini et al, 2006). Preclinical and clinical
studies (Shaked et al, 2005; Zhang et al, 2005; Bertolini et al, 2006;
Bhatt et al, 2007) have shown a correlation between CEC and EPC
numbers and the antiangiogenic activity of different drugs, and
thus, measurements of CEC and/or EPC have been proposed as
biomarkers for monitoring antiangiogenic drug activity (Bertolini
et al, 2006; Bhatt et al, 2007). To test the effect of ATN-224 on
EPCs, different cell surface markers were first evaluated for the
proper identification of EPCs using bonnet macaques as a model
that would identify markers that could be translated into humans.
Thus, EPCs were identified as CD31þ/CD133þ/CD45 weak and
measured in six bonnet macaques that were treated daily with
ATN-224 (0.5mgkg
 1, s.c.) for 22 days followed by a 26-day drug
holiday, and then 33 more days of treatment. The dose was chosen
based on bioavailability studies that showed bioequivalency of that
dose with a dose of 25mgkg
 1 in mice given orally (data not
shown). This dose was thought to be nontoxic, but sufficiently high
to inhibit angiogenesis. The monkeys readily adapted to the
experimental procedure, and exhibited no distress throughout.
No behavioural changes (e.g., activity or interactional behaviours)
were apparent across the course of the experiment, although mean
body weight of the monkeys decreased by 8% by the end of the
initial period of drug administration (P¼0.012). By the end of the
drug holiday, mean body weights had recovered to 95% of baseline
values. It was thought that the drug could be interfering with the
monkeys’ evening feeding and during the second round of drug
administration, ATN-224 was given 15min before the colony room
lights went off instead of the 30–90min of the first round.
Interestingly, mean body weights did not change during the course
of the second round of drug administration. All animals developed
mild alopecia during the first administration of ATN-224. This was
partially resolved during the drug holiday and second round of
ATN-224. The levels of EPCs increased initially at day 6 in five out
of the six subjects, and then decreased to 7% of baseline at day 21
(Figure 6). The EPC levels rebounded to normal levels once
treatment was discontinued and dropped again after treatment was
reinstated. All other parameters measured, for example, red and
white blood cell counts, platelets and haemoglobin levels were not
affected by treatment (data not shown). Although we did not
measure blood cell SOD in the macaque study, the recently
completed phase I study with ATN-224 (Lowndes et al, 2006)
indicated that substantial and maintained inhibition of blood cell
SOD was associated with haematologic toxicities. As we observed
significant depletion of EPCs in the macaques at a dose of ATN-
224 that does not affect haematologic parameters, it is unlikely that
we had significant inhibition of blood cell SOD in that study,
further supporting the hypothesis that doses at which red blood
cell (RBC) SOD activity is inhibited exceed the threshold required
for antiangiogenic activity. Therefore, measuring EPCs in patients
receiving ATN-224 may be a useful biomarker of antiangiogenic
activity.
DISCUSSION
The need for biomarkers in clinical development is clear and even
more important for noncytotoxic agents, which often do not cause
objective responses (Bhatt et al, 2007). Biomarkers are useful in
managing dosing and toxicity, monitoring clinical benefit and/or
in selecting patients more likely to benefit from the drug being
tested. Ideally, besides being informative, biomarker assays should
also be as minimally invasive as possible and preferably use tissue
samples that are readily accessible in patients. Here, we report the
evaluation of two possible biomarkers for ATN-224, the SOD
activity in blood and EPC levels also in blood that will be measured
during the clinical development of ATN-224. Both biomarker
assays are minimally invasive, requiring only simple blood samples
with minimal processing, and can be utilised to monitor biological
activity of ATN-224 and to manage dosing. The SOD activity can
be measured in blood pellets and tumour lysates, and is quickly
inhibited upon ATN-224 dosing. The PK of ATN-224 is followed by
tracking Mo in plasma (Berenson et al, 2006; Lowndes et al, 2006).
This approach, however, does not distinguish the active compound
from its metabolites. Despite our best efforts, no methodology has
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Figure 6 ATN-224 treatment lowers CECs and EPCs in monkeys. Six
bonnet macaques were treated daily with ATN-224 (0.5mgkg
 1, s.c.) for
22 days followed by a 26-day drug holiday and 33 more days of treatment.
The percentages of CD31þ/CD133þ/CD45 weak (EPCs) populations
measured by flow cytometry are shown for each animal at the indicated
time points on the X axis; *P¼0.021.
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sbeen found to track the active compound. An alternative approach
could be to follow a pharmacodynamic marker in blood that may
be a read-out of active drug exposure. The SOD activity in blood
pellets of mice treated with ATN-224 reflects the levels of ‘active’
compound, and the changes are observed very early after the
initiation of treatment in contrast to changes in Cp, which take
weeks of TM treatment to be observed (Brewer et al, 2000; Pan
et al, 2002, 2003a,b; Redman et al, 2003; Goodman et al, 2005;
Hassouneh et al, 2007). Thus, changes in the SOD activity in blood
may provide a sensitive barometer of drug exposure in animals
and humans.
The data in mice indicate that the concentrations needed to
inhibit the SOD activity in blood pellets (ED50B100–150mgkg
 1,
equivalent to B8–12mgkg
 1 in humans) are higher than the
doses that have been used in clinical trials (B3mgkg
 1 of TM,
equivalent to 5mgkg
 1 of ATN-224) (Brewer et al, 2000; Redman
et al, 2003), implying that the SOD inhibition in human blood may
not occur upon ATN-224 dosing. On the other hand, copper
deficiency in humans has been shown to correlate with decreased
SOD1 activity in RBC (Uauy et al, 1985; Milne, 1998), suggesting
that ATN-224, which lowers levels of systemic copper in humans,
should also inhibit SOD1. There are several possible reasons to
explain this discrepancy between humans and mice. For instance,
there may be differences among species as to the doses needed to
inhibit the SOD1 activity in blood cells, and, importantly, we have
shown that ATN-224 accumulates in cells (Juarez et al, 2006). This
suggests that longer treatments than those used in this study may
lower the threshold of ATN-224 needed for inhibiting blood cell
SOD1. Indeed, data from a phase I trial showed a profound and
persistent inhibition of SOD1 in blood pellets in patients treated at
several ATN-224 doses below and at the maximal tolerated dose
(Lowndes et al, 2006).
Inhibition of angiogenesis, as determined in the Matrigel plug
model, occurs at lower doses than those needed for the SOD1
inhibition in blood pellets of mice. This suggests that the SOD1
inhibition in blood pellets will be indicative of antiangiogenic
activity, since when a dose capable of inhibiting blood cell SOD1 is
achieved the threshold for antiangiogenic activity would have been
crossed. This is confirmed by the fact that at doses where SOD1
activity is beginning to be inhibited, there is already a significant
effect observed on EPC levels, a biomarker for angiogenesis. In
contrast, a lack of SOD1 inhibition would be noninformative with
respect to the inhibition of angiogenesis. The relationship between
the SOD1 inhibition in blood cells and antiangiogenic activity in
humans has been studied in a phase I trial (Lowndes et al, 2006).
It has been shown that ATN-224 has antiproliferative and/or
proapoptotic effects on tumour cells in vitro but only when SOD1
activity was inhibited almost 100% (Juarez et al, 2006). Inhibition
of the SOD activity in tumour-bearing animals treated with
ATN-224 for 10 days was 65–80% at a concentration that is
approximately two- to three-fold higher than the concentrations
reported for antitumour activity in mice, suggesting that ATN-224
may not be exerting a significant direct effect in tumour cells, at
least in a xenograft model. Alternatively, it is possible that SOD1
inhibition is not homogeneous throughout the tumour and that
areas exist in which SOD1 inhibition is complete and direct
antitumour activity may occur. Currently, a method for measuring
the SOD activity in fixed tissue is being developed to address
this question. Finally, a xenografted tumour in a mouse, which is
essentially a sphere of tumour cells, may not accurately reflect the
situation with respect to human cancer, whether significant
stromal components also exist in addition to the tumour cells
themselves. Thus, our data only provide a rationale for studying
the relationship of SOD1 inhibition to the inhibition of tumour
growth in humans but may not accurately predict a correlation or
lack thereof.
Endothelial progenitor cells have recently been used in several
animal studies and clinical trials to follow the activity of a variety
of antiangiogenic agents (Shaked et al, 2005; Zhang et al, 2005;
Bertolini et al, 2006; Bhatt et al, 2007), and this technique
continues to gain confirmation and acceptance as a promising
biomarker for the inhibition of angiogenesis. On the basis of the
results and rationale presented herein, SOD1 inhibition and
depletion of EPCs/CECs, as well as Cp levels, have been evaluated
for their ability to follow active drug and drug PD in a recently
completed phase I clinical trial in patients with advanced solid
cancer (Lowndes et al, 2006), and a paper describing these studies
has now been submitted for publication.
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